5 recruiting, 2 completed, 2 terminated, 2 withdrawn. 13 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Recruiting 5, Completed 2, Terminated 2, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Withdrawn 1 |
Follow Refractory AML: new trials by email Literature Review of Refractory AML trials Research Report on Refractory AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML CVA - Acute Myeloid Leukemia, Relapse | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-03-15 | 2025-02-24 |
| CART123 + Ruxolitinib in Relapsed/Refractory AML CART123 Cells, Ruxolitinib 10 MG, Ruxolitinib 5 MG - Relapsed AML, Refractory AML | Phase 1 | Active not recruiting | University of Pennsylvania | 12 | 2025-02-28 | 2026-01-16 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML Aza, tislelizumab - Refractory AML, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 | 2024-09-19 | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1 - Relapsed Adult AML, Refractory AML | Phase 1 | Withdrawn | Medical College of Wisconsin | 2024-08-31 | 2024-08-13 | |
| CLL-1 CAR-NK Cells for Relapsed/Refractory AML anti-CLL-1 CAR NK cells - Relapsed Adult AML, Refractory AML | Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 24 | 2024-04-01 | 2025-09-30 |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Recruiting | Kura Oncology, Inc. | 420 | 2023-07-18 | 2026-03-13 |
| An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia NEI-01 - Advanced Solid Tumor, Relapsed AML | Phase 1 | Unknown | New Epsilon Innovation Limited | 24 | 2022-04-25 | 2023-07-27 |
| Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Completed | Technische Universität Dresden | 55 | 2020-04-06 | 2026-09-02 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML | Phase 1 / Phase 2 | Recruiting | Aptose Biosciences Inc. | 240 | 2019-03-11 | 2025-08-26 |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia GEM333 - Acute Myeloid Leukemia, Relapsed AML | Phase 1 | Terminated | AvenCell Europe GmbH | 36 | 2018-04-11 | 2022-09-29 |
| Phase 1 Study of Quizartinib AC220 - Relapsed AML, Refractory AML | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 17 | 2016-02-01 | 2019-02-12 |
Leukemia, Myeloid, Acute (13) · Leukemia (3) · Recurrence (3) · Hematologic Neoplasms (2) · Neoplasms (2) · Hematologic Diseases (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasm, Residual (1) · Neoplasms by Histologic Type (1) · Sarcoma, Myeloid (1)
Hemic and Lymphatic Diseases (13) · Hematologic Diseases (12) · Leukemia, Myeloid (12) · Neoplasms by Histologic Type (12) · Neoplasms (11) · Leukemia (10) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Neoplasms by Site (2) · Bone Marrow Diseases (1) · Chronic Disease (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplastic Processes (1)
venetoclax (4) · Azacitidine (2) · Cytarabine (2) · Cladribine (1) · Cyclophosphamide (1) · Daunorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Infusions, Intravenous (1) · Interleukin-2 (1) · Mitoxantrone (1) · fludarabine (1) · navitoclax (1) · quizartinib (1) · ruxolitinib (1)
Aptose Biosciences Inc. (1) · AvenCell Europe GmbH (1) · Celularity Incorporated (1) · Daiichi Sankyo Co., Ltd. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kura Oncology, Inc. (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · New Epsilon Innovation Limited (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Technische Universität Dresden (1) · The First Affiliated Hospital of Xiamen University (1) · University of Pennsylvania (1)
United States (6) · China (3) · Germany (3) · Australia (1) · Hong Kong (1) · Japan (1) · New Zealand (1) · South Korea (1) · Spain (1)
Bing Xu (1) · Christine Kwok, PhD (1) · Guru Subramanian Guru Murthy, MD, MS (1) · Martin Wermke, MD (1) · Naval Daver, MD (1) · Saar Gill, MD, PhD (1) · Sharmila Koppisetti, M.D (1)
PMID 31359361, PMID 39665627, PMID 41791831, PMID 42227701
2017 (1), 2023 (1)